Anaphylaxis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Anaphylaxis – Pipeline Review, H1 2020’, provides an overview of the Anaphylaxis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaphylaxis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Anaphylaxis

– The report reviews pipeline therapeutics for Anaphylaxis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Anaphylaxis therapeutics and enlists all their major and minor projects

– The report assesses Anaphylaxis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Anaphylaxis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Anaphylaxis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Anaphylaxis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aquestive Therapeutics Inc

ARS Pharmaceuticals Inc

Bryn Pharma LLC

G2B Pharma Inc

Insys Therapeutics Inc

JDP Therapeutics Inc

MannKind Corp

Merck & Co Inc

Shenox Pharmaceuticals LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Anaphylaxis - Overview

Anaphylaxis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anaphylaxis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anaphylaxis - Companies Involved in Therapeutics Development

Aquestive Therapeutics Inc

ARS Pharmaceuticals Inc

Bryn Pharma LLC

G2B Pharma Inc

Insys Therapeutics Inc

JDP Therapeutics Inc

MannKind Corp

Merck & Co Inc

Shenox Pharmaceuticals LLC

Anaphylaxis - Drug Profiles

epinephrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epinephrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epinephrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epinephrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epinephrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

epinephrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JDP-207 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmonary Inflammation, Systemic Anaphylaxis and Thrombocytopenia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHX-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-499 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anaphylaxis - Dormant Projects

Anaphylaxis - Product Development Milestones

Featured News & Press Releases

May 04, 2020: Neurelis announces that Intravail Licensee, ARS Pharmaceuticals intranasal epinephrine product, demonstrates bioequivalent exposure to epinephrine injectors

Apr 06, 2020: Bryn Pharma presents data demonstrating comparable pharmacokinetic and pharmacodynamic effects of intranasal Epinephrine to intramuscular Epinephrine in adults

Mar 02, 2020: ARS Pharmaceuticals to present new data from Neffy (ARS-1) studies at AAAAI 2020 annual meeting

Feb 06, 2020: Aquestive Therapeutics announces FDA confirmed 505(b)(2) pathway for AQST-108 (sublingual film formulation delivering systemic epinephrine) for anaphylaxis treatment

Nov 10, 2019: Bryn Pharma Research on Epinephrine Nasal Spray Presented at The American College of Allergy, Asthma and Immunology Annual Meeting

Oct 29, 2019: Bryn Pharma presents data demonstrating patient preference for bi-dose epinephrine nasal spray over EpiPen

Oct 10, 2019: Bryn Pharma completes dosing in pivotal clinical trial designed to support U.S. approval of Intranasal Epinephrine Spray

Sep 30, 2019: Aquestive Therapeutics Announces Successful Completion of Phase 1 Trial for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine)

Jun 04, 2019: ARS Pharmaceuticals announces results from EPI-04 clinical study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis

Feb 25, 2019: INSYS Therapeutics presented poster of initial pharmacokinetic study of Epinephrine Nasal Spray for the emergency treatment of allergic reactions (Type I) including anaphylaxis at American Academy of Allergy, Asthma and Immunology Annual Meeting

Feb 19, 2019: ARS Pharmaceuticals announces FDA Fast Track Designation for ARS-1 intranasal epinephrine spray

Dec 19, 2018: ARS Pharmaceuticals advances clinical program for intranasal epinephrine spray

Dec 17, 2018: INSYS Therapeutics provides update on Epinephrine nasal spray for anaphylaxis

Aug 30, 2018: FDA Grants INSYS Therapeutics Fast Track Designation for Epinephrine Nasal Spray as Investigational Treatment for Anaphylaxis

Jun 14, 2018: Epinephrine Nasal Spray in Development for Treatment of Anaphylaxis Shows Promise as Potential Alternative to Intramuscular Injection

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Anaphylaxis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Anaphylaxis – Pipeline by Aquestive Therapeutics Inc, H1 2020

Anaphylaxis – Pipeline by ARS Pharmaceuticals Inc, H1 2020

Anaphylaxis – Pipeline by Bryn Pharma LLC, H1 2020

Anaphylaxis – Pipeline by G2B Pharma Inc, H1 2020

Anaphylaxis – Pipeline by Insys Therapeutics Inc, H1 2020

Anaphylaxis – Pipeline by JDP Therapeutics Inc, H1 2020

Anaphylaxis – Pipeline by MannKind Corp, H1 2020

Anaphylaxis – Pipeline by Merck & Co Inc, H1 2020

Anaphylaxis – Pipeline by Shenox Pharmaceuticals LLC, H1 2020

Anaphylaxis – Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development for Anaphylaxis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports